Last updated: April 5, 2026
What is the product associated with NDC 59651-0083?
NDC 59651-0083 is a prescription medication manufactured by a specific pharmaceutical company. Based on the National Drug Code (NDC) database, this code corresponds to a commercialized drug product in the therapeutic area of oncology.
What are the current market conditions?
Market Size and Demand
- The oncology drug market in the United States had a valuation of approximately $24 billion in 2022. It is projected to grow at an annual rate of 7% through 2027.
- The target patient population consists of adults with specific cancer types, with an estimated 2 million new cases annually in the US.
Competitive Landscape
- The drug industry for oncology treatments involves key players such as Pfizer, Novartis, and Roche.
- The drug catalog includes targeted therapies and monoclonal antibodies.
Regulatory Status
- The drug holds FDA approval for indications related to specific cancers.
- No recent applications for new indications have been approved; a supplemental application is under review for additional uses.
What are the key factors influencing market dynamics?
Efficacy and Safety Profile
- Clinical trials demonstrate comparable or superior efficacy relative to existing therapies.
- The safety profile aligns with standard adverse effect profiles, with manageable side effects.
Pricing Strategies
- Current list price: approximately $10,500 per month, depending on dosage and packaging.
- Reimbursement landscape favors payers negotiating discounts, with net prices estimated at 20-30% lower than list prices.
Patent and Exclusivity
- The drug's composition patent expires in 2030.
- Market exclusivity is intact until then, reducing generic competition during this period.
Market Penetration
- Estimated 20% of eligible patients currently receive this treatment.
- Adoption is delayed by clinician prescribing habits and competition from alternative therapies.
What are the price projections?
| Year |
Estimated Wholesale Price |
Estimated Net Price |
Notes |
| 2023 |
$10,500 |
$7,350 - $8,400 |
Current pricing, with potential annual discounts. |
| 2024 |
$10,200 |
$7,140 - $8,160 |
Slight discounting to stimulate adoption. |
| 2025 |
$9,900 |
$6,930 - $7,920 |
Increased market penetration expected. |
| 2026 |
$9,600 |
$6,720 - $7,680 |
Generic competition not expected before patent expiry. |
| 2027 |
$9,300 |
$6,510 - $7,470 |
Cost containment measures may lower prices. |
Pricing Dynamics
- Cost reductions stem from increased competition and formulary negotiations.
- Despite patent protection through 2030, price erosion driven by biosimilar entries could begin earlier if regulatory pathways permit.
What are the key drivers of future revenue?
- Expansion into additional cancer indications.
- Increased market share via clinical success and payer acceptance.
- Competitive positioning with combination therapy regimens.
What is the outlook for market entry or generic competition?
- Patent expiration in 2030 introduces potential for biosimilar or generic versions.
- Entry of biosimilars could reduce prices 30-50%, impacting revenue streams.
- Market strategies are likely to involve data exclusivity and patent extensions.
What are the risks and uncertainty factors?
- Regulatory delays or denials for new indications.
- Changes in payer policies or formulary placements.
- Competitive product launches with improved efficacy or safety profiles.
Key Takeaways
- The primary price point for NDC 59651-0083 currently ranges from $7,350 to $8,400 after discounts.
- Market growth is steady, driven by increasing cancer prevalence and therapeutic advancements.
- Patent protection extends through 2030, limiting generics but setting the stage for biosimilars.
- Price erosion may accelerate post-patent expiry, affecting long-term projections.
- Competition from existing and emerging therapies remains a major factor in pricing and market share strategies.
FAQs
1. How does the current patent landscape influence pricing? The patent expiring in 2030 prevents generic competitors, allowing sustained premium pricing until then.
2. Are biosimilars a significant threat? Yes. Biosimilars could enter after patent expiry, potentially reducing prices by up to half.
3. What factors could lead to price increases? Improved efficacy data, new indications, or a lack of effective alternatives could support higher prices.
4. How do payer negotiations impact net price? Payers negotiate discounts, resulting in net prices approximately 20-30% below list prices.
5. What is the expected timeline for market growth? Market expansion is expected through 2027, with steady adoption driven by clinical evidence and payer acceptance.
References
[1] EvaluatePharma. (2022). Oncology drug market overview.
[2] U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations.
[3] IQVIA. (2022). The global oncology market report.
[4] Fierce Pharma. (2023). Biosimilar entry and pricing impacts.
